396 related articles for article (PubMed ID: 11136282)
21. Effect of Helicobacter pylori infection on gastric juice pH.
Furuta T; Baba S; Takashima M; Futami H; Arai H; Kajimura M; Hanai H; Kaneko E
Scand J Gastroenterol; 1998 Apr; 33(4):357-63. PubMed ID: 9605256
[TBL] [Abstract][Full Text] [Related]
22. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
[TBL] [Abstract][Full Text] [Related]
23. Helicobacter pylori infection. A reversible cause of hypergastrinemia and hyperchlorhydria which may mimic Zollinger-Ellison syndrome.
Metz DC; Weber HC; Orbuch M; Strader DB; Lubensky IA; Jensen RT
Dig Dis Sci; 1995 Jan; 40(1):153-9. PubMed ID: 7821103
[TBL] [Abstract][Full Text] [Related]
24. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
25. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
[TBL] [Abstract][Full Text] [Related]
26. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
27. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Geboes K; Dekker W; Mulder CJ; Nusteling K;
Aliment Pharmacol Ther; 2001 Nov; 15(11):1819-26. PubMed ID: 11683696
[TBL] [Abstract][Full Text] [Related]
28. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
29. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.
Tomassetti P; Salomone T; Migliori M; Campana D; Corinaldesi R
Drugs Aging; 2003; 20(14):1019-34. PubMed ID: 14651442
[TBL] [Abstract][Full Text] [Related]
30. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
31. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
32. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia.
Annibale B; Aprile MR; D'ambra G; Caruana P; Bordi C; Delle Fave G
Aliment Pharmacol Ther; 2000 May; 14(5):625-34. PubMed ID: 10792127
[TBL] [Abstract][Full Text] [Related]
33. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
Bardram L; Thomsen P; Stadil F
Digestion; 1986; 35 Suppl 1():116-22. PubMed ID: 3792668
[TBL] [Abstract][Full Text] [Related]
34. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
[TBL] [Abstract][Full Text] [Related]
35. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
[TBL] [Abstract][Full Text] [Related]
37. Proton-pump inhibitors for gastric acid-related disease.
Franko TG; Richter JE
Cleve Clin J Med; 1998 Jan; 65(1):27-34. PubMed ID: 9465453
[TBL] [Abstract][Full Text] [Related]
38. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
39. Helicobacter pylori and Zollinger-Ellison syndrome.
Saeed ZA; Evans DJ; Evans DG; Cornelius MJ; Maton PN; Jensen RT; Graham DY
Dig Dis Sci; 1991 Jan; 36(1):15-8. PubMed ID: 1984998
[TBL] [Abstract][Full Text] [Related]
40. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
